Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 78-83

  Besse, Benjamin ^a   Planchard, David ^a   Veillard, Anne Sophie ^a   Taillade, Laurent ^b   Khayat, David ^b   Ducourtieux, Muriel ^a   Pignon, Jean Pierre ^a   Lumbroso, Jean ^a   Lafontaine, Carole ^a   Mathiot, Claire ^c   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT CURIE   (France)

Author keywords

Bortezomib; Frontline; Non small cell lung cancer; Phase II

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUORODEOXYGLUCOSE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APLASIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CACHEXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REST; SENSORY NEUROPATHY; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL DISORDER;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PYRAZINES; SURVIVAL RATE;

EID: 84858004995     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.006     Document Type: Article

References (27)

1. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Reck M., Von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
4. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
5. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
6. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
7. Tsao M.S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5240-5247.
8. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
9. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
10. Shah J.J., Orlowski R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23:1964-1979.
11. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002, 8:2505-2511.
12. Stevenson J.P., Nho C.W., Johnson S.W., Evans T.L., Algazy K.A., Gallagher M., et al. Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: a phase II/pharmacodynamic trial. J Clin Oncol (Meeting Abstracts) 2004, 22:7145.
13. Fanucchi M.P., Fossella F.V., Belt R., Natale R., Fidias P., Carbone D.P., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5025-5033.
14. Giaccone G., Gallegos R.M., Le Chevalier T., Thatcher N., Smit E., Rodriguez J.A., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006, 12:6049-6055.
15. Johnson F.M., Bekele B.N., Feng L., Wistuba I., Tang X.M., Tran H.T., et al. Phase II study of dasatinib in patients with advanced non small-cell lung cancer. J Clin Oncol 2010, 28:4609-4615.
16. Li T., Ho L., Piperdi B., Elrafei T., Camacho F.J., Rigas J.R., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 2010, 68:89-93.
17. Scagliotti G.V., Germonpre P., Bosquee L., Vansteenkiste J., Gervais R., Planchard D., et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010, 68:420-426.
18. Davies A.M., Ho C., Metzger A.S., Beckett L.A., Christensen S., Tanaka M., et al. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol 2007, 2:1112-1116.
19. Lara P.N., Koczywas M., Quinn D.I., Lenz H.J., Davies A.M., Lau D.H., et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol 2006, 1:126-134.
20. Davies A.M., Ruel C., Lara P.N., Lau D.H., Gumerlock P.H., Bold R., et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol 2008, 3:68-74.
21. Voortman J., Smit E.F., Honeywell R., Kuenen B.C., Peters G.J., van de Velde H., et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007, 13:3642-3651.
22. Lilenbaum R., Wang X., Gu L., Kirshner J., Lerro K., Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 2009, 27:4487-4491.
23. Lynch T.J., Fenton D., Hirsh V., Bodkin D., Middleman E.L., Chiappori A., et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009, 4:1002-1009.
24. Dudek A.Z., Lesniewski-Kmak K., Shehadeh N.J., Pandey O.N., Franklin M., Kratzke R.A., et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009, 100:1379-1384.
25. Karapetis C.S., Clingan P.R., Leighl N.B., Durbin-Johnson B., O'Neill V., Spigel D.R. Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2010, 28:7535.
26. Blackhall F.H., Mark Z., Zatloukal P., Szima B., Albert I., Juhasz E., et al. A randomized phase II study of paclitaxel (P) and carboplatin (C) {+/-} bevacizumab (B) {+/-} dulanermin (D) in non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2010, 28:7534.
27. Voortman J., Pham T.V., Knol J.C., Giaccone G., Jimenez C.R. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci 2009, 7:34.